Secondary Acute Myeloid Leukemia Clinical Trials

149 clinical trials for Secondary Acute Myeloid Leukemia across international registries, including 8 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Personalized NK Cell Therapy in CBT — RECRUITING · PHASE2
• A Phase 1b Study of Menin Inhibitor SNDX- 5613 in Combination With Daunorubicin and Cytarabine in Newly Diagnosed Patients With Acute Myeloid Leukemia and NPM1 Mutated/FLT3 Wildtype or MLL/KMT2A Rearranged or NUP98 Alterations Disease — RECRUITING · PHASE1
• Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia — RECRUITING · PHASE2
• Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Adults With Myeloid Malignancies at High Risk of Relapse — RECRUITING · PHASE1
• CD33-CAR T Cell Therapy for the Treatment of Recurrent or Refractory Acute Myeloid Leukemia — RECRUITING · PHASE1
• Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy — RECRUITING · PHASE1
• Venetoclax in Addition to Sequential Conditioning With Fludarabine / Amsacrine / Ara-C (FLAMSA) + Treosulfan for Allogeneic Blood Stem Cell Transplantation in Patients With MDS, CMML or sAML — RECRUITING · PHASE1
• Unrelated Umbilical Cord Blood Stem Cell Combined With Azacitidine Based Treatment for Advanced MDS,CMML-2 and sAML — RECRUITING · PHASE1
• Eltrombopag Olamine in Improving Platelet Recovery in Older Patients With Acute Myeloid Leukemia Undergoing Chemotherapy — COMPLETED · PHASE2
• BLAST MRD AML-2: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 2- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Azacitidine and Venetoclax as Frontline Therapy in Unfit Patients With Acute Myeloid Leukemia — ACTIVE_NOT_RECRUITING · PHASE2
• Hu8F4 in Treating Patients With Advanced Hematologic Malignancies — ACTIVE_NOT_RECRUITING · PHASE1
• Bortezomib, Sorafenib Tosylate, and Decitabine in Treating Patients With Acute Myeloid Leukemia — ACTIVE_NOT_RECRUITING · PHASE1
• 90Y-DOTA-anti-CD25 Basiliximab, Fludarabine, Melphalan, and Total Marrow and Lymphoid Irradiation for the Treatment of High-Risk Acute Leukemia or Myelodysplastic Syndrome — ACTIVE_NOT_RECRUITING · PHASE1
• Total Marrow and Lymphoid Irradiation, Fludarabine, and Melphalan Before Donor Stem Cell Transplant in Treating Participants With High-Risk Acute Leukemia or Myelodysplastic Syndrome — SUSPENDED · PHASE1
• Azacitidine and Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia — ACTIVE_NOT_RECRUITING · PHASE2
• BLAST MRD AML-1: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 1- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Intensive Chemotherapy as Frontline Therapy in Patients With Acute Myeloid Leukemia — ACTIVE_NOT_RECRUITING · PHASE2
• Testing a New Chemotherapy Drug, KRT-232 (AMG-232) in Combination With Decitabine and Venetoclax in Patients With Acute Myeloid Leukemia — ACTIVE_NOT_RECRUITING · PHASE1
• Uproleselan, Cladribine, and Low Dose Cytarabine for the Treatment of Patients With Treated Secondary Acute Myeloid Leukemia — COMPLETED · PHASE1
• CPX-351 in Treating Patients With Newly Diagnosed, High-Risk Acute Myeloid Leukemia — COMPLETED · PHASE2
• Daunorubicin Hydrochloride, Cytarabine and Oblimersen Sodium in Treating Patients With Previously Untreated Acute Myeloid Leukemia — COMPLETED · PHASE3
• Biomarkers in Predicting Treatment Response to Sirolimus and Chemotherapy in Patients With High-Risk Acute Myeloid Leukemia — COMPLETED · PHASE2
• Cognitive Behavioral Therapy in Helping Patients With Acute Myeloid Leukemia or Lymphoma With Cancer-Related Fatigue — ACTIVE_NOT_RECRUITING · PHASE2
• Liposomal Cytarabine, Daunorubicin, and Gemtuzumab Ozogamicin for the Treatment of Relapsed Refractory Pediatric Patients With Acute Myeloid Leukemia — COMPLETED · PHASE1
• A Proof of Concept Pilot Study of the Addition of Venetoclax to Standard Remission Induction Chemotherapy Fludarabine or Cladrabine, Cytarabine, and Granulocyte Colony Stimulating Factor (G-CSF) (FLAG or CLAG) for Frontline Therapy of Secondary Acute Myeloid Leukemia — TERMINATED · PHASE2
• Ipilimumab and Decitabine in Treating Patients With Relapsed or Refractory Myelodysplastic Syndrome or Acute Myeloid Leukemia — ACTIVE_NOT_RECRUITING · PHASE1
• Decitabine, Cytarabine, and Daunorubicin Hydrochloride in Treating Patients With Acute Myeloid Leukemia — ACTIVE_NOT_RECRUITING · PHASE2
• Testing the Effect of Taking Ruxolitinib and CPX-351 in Combination for the Treatment of Advanced Phase Myeloproliferative Neoplasms — TERMINATED · PHASE1
• Pevonedistat and Decitabine in Treating Patients With High Risk Acute Myeloid Leukemia — COMPLETED · PHASE1
• Testing the Use of Combination Therapy in Patients With Persistent Low Level Acute Myeloid Leukemia Following Initial Treatment, The ERASE Study (A MyeloMATCH Treatment Trial) — NOT_YET_RECRUITING · PHASE2
• Geriatric Assessment & Genetic Profiling to Personalize Therapy in Older Adults With Acute Myeloid Leukemia — COMPLETED · PHASE2
• CD8 Depleted, Non-engrafting, HLA Mismatched Unrelated Infusion With MDS and Secondary AML — COMPLETED · PHASE1
• Phase I Trial of AZD1775 and Belinostat in Treating Patients With Relapsed or Refractory Myeloid Malignancies or Untreated Acute Myeloid Leukemia — TERMINATED · PHASE1
• Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant — ACTIVE_NOT_RECRUITING
• CPX-351 for the Treatment of Secondary Acute Myeloid Leukemia in Patients Younger Than 60 Years Old — ACTIVE_NOT_RECRUITING · PHASE2
• Veliparib and Temozolomide in Treating Patients With Acute Leukemia — COMPLETED · PHASE1
• Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in With High-Risk Hematologic Malignancies — COMPLETED · PHASE2
• Genetically Modified T-cell Immunotherapy in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia and Persistent/Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm — ACTIVE_NOT_RECRUITING · PHASE1
• Hematopoietic Stem Cell Transplantation in the Treatment of Infant Leukemia — COMPLETED · PHASE2
• Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood Cancer — TERMINATED · PHASE2
• Nivolumab and Azacitidine With or Without Ipilimumab in Treating Patients With Refractory/Relapsed or Newly Diagnosed Acute Myeloid Leukemia — COMPLETED · PHASE2
• Vosaroxin and Infusional Cytarabine in Treating Patients With Untreated Acute Myeloid Leukemia — COMPLETED · PHASE2
• Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia — COMPLETED · PHASE3
• Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant — COMPLETED · PHASE1
• Liposome-encapsulated Daunorubicin-Cytarabine, Fludarabine Phosphate, Cytarabine, and Filgrastim in Treating Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia — COMPLETED · PHASE1
• Selinexor and Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia — COMPLETED · PHASE1
• Salsalate, Venetoclax, and Decitabine or Azacitidine for the Treatment of Acute Myeloid Leukemia or Advanced Myelodysplasia/Myeloproliferative Disease — COMPLETED · PHASE2
• Combination Chemotherapy and Dasatinib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia — COMPLETED · PHASE2
• TP-0903 for the Treatment of FLT3 Mutated Acute Myeloid Leukemia — COMPLETED · PHASE1
• Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies — TERMINATED · PHASE2
• Iodine I 131 Monoclonal Antibody BC8, Fludarabine Phosphate, Total Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients With Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome — TERMINATED · PHASE2

Refine this search